Angiogenesis: A promising therapeutic target for ovarian cancer

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 3, 2012, Pages 314-326

  Bamias, A ^a   Pignata, S ^b   Pujade Lauraine, E ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

AMG386; Angiogenesis; Bevacizumab; Cediranib; Ovarian cancer; Pazopanib; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A.4.6.1; NINTEDANIB; OLAPARIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADD ON THERAPY; ADVANCED CANCER; ANASTOMOSIS LEAKAGE; ANGIOGENESIS; ASCITES; ASCITES TUMOR CELL; BLEEDING; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN DISEASE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CARCINOGENESIS; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM BLEEDING; CENTRAL NERVOUS SYSTEM DISEASE; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG TARGETING; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GYNECOLOGIC CANCER; HAND FOOT SYNDROME; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; IMMUNE DEFICIENCY; KIDNEY DISEASE; KIDNEY FAILURE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; NAUSEA; OVARY CANCER; OVARY CARCINOMA; PERITONEUM CANCER; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SIDE EFFECT; SKIN TOXICITY; THROMBOEMBOLISM; TRIPLE NEGATIVE BREAST CANCER; UTERINE TUBE CARCINOMA; VOMITING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS;

EID: 84870313971     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.04.002     Document Type: Review

References (93)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA: A Cancer Journal for Clinicians 2009, 59:225-249.
2. Bristow R.E., Puri I., Chi D.S. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecologic Oncology 2009, 112:265-274.
3. Bamias A., Sotiropoulou M., Zagouri F., et al. Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor. European Journal of Cancer 2011, 10.1016/j.ejca.2011.09.023.
4. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2003, 21:3194-3200.
5. Pliarchopoulou K., Pectasides D. Epithelial ovarian cancer: focus on targeted therapy. Critical Reviews in Oncology/Hematology 2011, 79:17-23.
6. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
7. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Journal of Clinical Oncology 2002, 20:4368-4380.
8. Spannuth W.A., Sood A.K., Coleman R.L. Angiogenesis as a strategic target for ovarian cancer therapy. Nature Clinical Practice: Oncology 2008, 4:194-204.
9. Shibuya M., Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Experimental Cell Research 2006, 312:549-560.
10. Burger R.A. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology 2011, 121:230-238.
11. Kerbel R.S. Tumor angiogenesis. New England Journal of Medicine 2008, 358:2039-2049.
12. Trinh X.B., Tjalma W.A., Vermeulen P.B., et al. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. British Journal of Cancer 2009, 100:971-978.
13. Chen H., Ye D., Xie X., Chen B., Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecologic Oncology 2004, 94:630-635.
14. Evans C., Dalgleish A.G., Kumar D. Review article: immune suppression and colorectal cancer. Alimentary Pharmacology and Therapeutics 2006, 24:1163-1177.
15. Barnett B., Krysczek I., Cheng P., Zou W., Curiel T.J. Regulatory T cells in ovarian cancer: biology and therapeutic potential. American Journal of Reproductive Immunology 2005, 54:369-377.
16. Kim R., Emi M., Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive network for tumor immunity. Immunology 2006, 119:254-264.
17. Bellati F., Napoletano C., Gasparri M.L., et al. Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms. Critical Reviews in Oncology/Hematology 2011, 10.1016/j.critrevonc.2011.09.006.
18. Papamichail M., Perez S.A., Gritzapis A.D., Baxevanis C.A. Natural killer lymphocytes: biology, development and function. Cancer Immunology, Immunotherapy 2004, 53:176-186.
19. Lim S.H., Newland A.C., Kelsey S., et al. Continuous intravenous infusion of high dose recombinant interleukin-2 for acute myeloid leukaemia - a phase II study. Cancer Immunology, Immunotherapy 1992, 34:337-342.
20. Ohm J.E., Gabrilovich D.I., Sempowski G.D., et al. Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynaecological tumor cells. Blood 2003, 101:4878-4886.
21. Dikov M.M., Ohm J.E., Ray N., et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. Journal of Immunology 2005, 174:215-222.
22. Lissoni P., Malugani F., Bonfanti A., et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. Journal of Biological Regulators and Homeostatic Agents 2001, 15:140-144.
23. Ziogas A.C., Gavalas N., Tsiatas M., et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. International Journal of Cancer 2012, 130:857-864.
24. Fan F., Wey J.S., McCarty M.F., et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005, 24:2647-2653.
25. Massod R., Cai J., Zheng T., Smith D.L., Hinton D.R., Gill P.S. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001, 98:1904-1913.
26. Sher I., Adham S.A., Petrik J., Coomber B.L. Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. International Journal of Cancer 2009, 124:553-561.
27. Rudlowski C., Pickart A.K., Fuljham C., et al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. International Journal of Gynecological Cancer 2006, 16(Suppl. 1):183-189.
28. Bamias A., Koutsoukou V., Terpos E., et al. Correlation of NK-T like CD3+ CD56+ cells and CD4+ CD25+(hi), regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first line, platinum based chemotherapy. Gynecologic Oncology 2008, 108:421-427.
29. Chen C.A., Cheng W.F., Lee C.N., et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecologic Oncology 1999, 74:235-240.
30. Alvarez Secord A., Sayer R., Snyder S.A., et al. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second look laparotomy in ovarian cancer. Gynecologic Oncology 2004, 94:74-79.
31. Bozas G., Terpos E., Gika D., Karadimou A., Dimopoulos M.A., Bamias A. Prechemotherapy serum levels of CD105. Transforming Growth Factor beta2, and Vascular Endothelial Growth Factor are associated with prognosis in patients with advanced epithelial ovarian cancer treated with cytoreductive surgery and platinum-based chemotherapy. International Journal of Gynecological Cancer 2010, 20:248-254.
32. Goodheart M.J., Ritcie J.M., Rose S.L., Fruehauf J.P., De Young B.R., Buller R.E. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clinical Cancer Research 2005, 11:3733-3742.
33. Vysotskii M.M., Digaeva M.A., Kushlinskii N.E., et al. Serum sFas, leptin, and VEGF in patients with ovarian cancer and benign tumors. Bulletin of Experimental Biology and Medicine 2009, 148:810-814.
34. Sallinen H., Antilla M., Narvainen J., et al. Antiangiogenic gene therapy with soluble VRGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Molecular Therapy 2009, 17:278-284.
35. Warren R.S., Yuan H., Matli M.R., Gillett N.A., Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. Journal of Clinical Investigation 1995, 95:1789-1795.
36. Hicklin D.J., Ellis L.M. Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology 2005, 23:1011-1027.
37. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004, 350:2335-2342.
38. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology 2007, 25:1539-1544.
39. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine 2006, 355:2542-2550.
40. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine 2007, 357:2666-2676.
41. Burger R., Brady M.F., Bookman M.A., et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. Journal of Clinical Oncology 2010, 28(Suppl.):18s. [Abstr. LBA1].
42. Oikawa T., Onozawa C., Sakaguchi M., Morita I., Murota S. Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivo. Biological and Pharmaceutical Bulletin 1994, 17:1686-1688.
43. Lu C., Thacker P.H., Lin Y.G., et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. American Journal of Obstetrics and Gynecology 2008, 198:477-479.
44. Erber R., Thurner A., Katsen A.D., et al. Combined inhibition of VEGF and PDGF signalling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell surviving mechanisms. FASEB Journal 2004, 18:338-340.
45. Berger G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation 2003, 111:1287-1295.
46. Lassus H., Sihto H., Leminen A., et al. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. British Journal of Cancer 2004, 91:2048-2055.
47. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
48. Cascone T., Heymach J.V. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?. Journal of Clinical Oncology 2012, 30:441-444.
49. Yu Y., Varughese J., Brown L.F., Mulliken J.B., Bischoff J. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. American Journal of Pathology 2001, 159:2271-2280.
50. Ahmad S.A., Liu W., Jung Y.D., et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Research 2001, 61:1255-1259.
51. Oliner J., Min H., Leal J., Yu D., Rao S., You E. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.
52. Coxon A., Bready J., Min H., et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Molecular Cancer Therapeutics 2010, 9:2641-2651.
53. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nature Medicine 2003, 9:669-676.
54. Burger R.A. Experience with bevacizumab in the management of epithelial ovarian cancer. Journal of Clinical Oncology 2007, 25:2902-2908.
55. Burger R.A., Sill M.W., Monk B.J., Greer B.E., Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2007, 25:5165-5171.
56. Cannistra S.A., Matulonis U.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. Journal of Clinical Oncology 2007, 25:5180-5186.
57. Han E.S., Monk B.J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?. Gynecologic Oncology 2007, 105:3-6.
58. Penson R.T., Dizon D.S., Cannistra S.A., et al. Phase II study of carboplatin, paclitaxel, and bevacizumab as first-line chemotherapy for advanced mullerian tumors. Journal of Clinical Oncology 2010, 28:154-159.
59. Rose P.G., Drake R., Braly P.S., et al. Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. Journal of Clinical Oncology 2009, 27(Suppl.):15S. [Abstract 5546].
60. Konner J.A., Grabon D.M., Gerst S.R., et al. Phase II study of intraperitoneal paclitaxel plus carboplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. Journal of Clinical Oncology 2011, 29:4662-4668.
61. Gonzales-Martin A., Gladieff L., Stroyakovskiy D., et al. Front-line bevacizumab combined with weekly paclitaxel and carboplatin for ovarian cancer: safety results from the concurrent chemotherapy phase of the OCTAVIA study. European Journal of Cancer 2011, 47(Suppl. 1):S528. [Abstract 8002].
62. Katsumata N., Yasuda M., Takahashi F., et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:1331-1338.
63. Garcia A.A., Hirte H., Fleming G., et al. Phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. Journal of Clinical Oncology 2008, 26:76-82.
64. Tillmanns T.D., Lowe M.P., Schwartzberg L.S., Walker M.S., Stepanski E.J. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum resistant primary epithelial ovarian or primary peritoneal carcinoma. Journal of Clinical Oncology 2010, 28(Suppl.):15S. [Abstract 5009].
65. Horowitz N.S., Penson R.T., Duda D.G., et al. Safety, efficacy, and biomarker exploration in a phase II study of bevacizumab, oxaliplatin, and gemcitabine in recurrent müllerian carcinoma. Clinical Ovarian Cancer & Other Gynecologic Malignancies 2011, 4:26-33.
66. Burger R.A., Brady M.F., Bookman M.A., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine 2011, 365:2473-2483.
67. Perren T., Swart A.M., Pfisterer J., et al. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine 2011, 365:2484-2496.
68. Aghajanian C., Finkler J.N., Rutherford T., et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Journal of Clinical Oncology 2011, 29(Suppl.):LBA5007.
69. Lockhart C., Rothenberg M.L., Dupont J., et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. Journal of Clinical Oncology 2009, 28:207-214.
70. Tew W.P., Colombo N., Ray-Coquard I., et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. Journal of Clinical Oncology 2007, 25(18S). [Abstract 5508].
71. Coleman R.L., Duska L.R., Ramirez P.T., et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncology 2011, 12:1109-1117.
72. Spratlin J.L., Cohen R.B., Eadens M., et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. Journal of Clinical Oncology 2010, 28:780-787.
73. Friedlander M., Hancock K.C., Rischin D., et al. A phase II open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecologic Oncology 2010, 119:32-37.
74. Tan A.R., Dowlati A., Jones S.F., et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 2010, 15(12):1253-1261.
75. du Bois A., Vergote I., Wimberger P., et al. Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group. British Journal of Cancer 2012, 106:629-632.
76. Matulonis U.A., Berlin S., Ivy P., et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. Journal of Clinical Oncology 2009, 27:5601-5606.
77. Hirte H.W., Vidal L., Fleming G.F., et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. Journal of Clinical Oncology 2008, 26(Suppl.). [Abstract 5521].
78. Liu J., Fleming G.F., Tolaney S.M., et al. A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer. Journal of Clinical Oncology 2011, 29(Suppl.). [Abstract 5028].
79. Ledermann J.A., Hackshaw A., Kaye S., et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. Journal of Clinical Oncology 2011, 29:3798-3804.
80. Biagi J.J., Oza A.M., ChalCha H.I., et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Annals of Oncology 2011, 22:335-340.
81. Bodnar L., Górnas M., Szczylik C. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecologic Oncology 2011, 123:33-36.
82. Matei D., Sill M.W., Lankes H.A., et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group Trial. Journal of Clinical Oncology 2010, 29:69-75.
83. Welch S.A., Hirte W.H.M.D., Elit L., et al. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer. A study of the Princess Margaret Hospital Phase II Consortium. International Journal of Gynecological Cancer 2010, 20:787-793.
84. Pölcher M., Eckhardt M., Coch C., et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemotherapy and Pharmacology 2010, 66:203-207.
85. Lee J.M., Saros G.A., Annunziata C.M., et al. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. British Journal of Cancer 2010, 102:495-499.
86. Karlan B.Y., Oza A.M., Richardson G.E., et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. Journal of Clinical Oncology 2012, 30:362-371.
87. Lu J.F., Rasmussen E., Karlan B.Y., et al. Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemotherapy and Pharmacology 2012, 10.1007/s00280-011-1787-5.
88. Cohn D.E., Kim K.H., Resnick K.E., O'Malley D.M., Straughn J.M. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. Journal of Clinical Oncology 2011, 29:1247-1251.
89. Hensley M.L. Big costs for little gain in ovarian cancer. Journal of Clinical Oncology 2011, 29:1230-1232.
90. Alberts D.S., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New England Journal of Medicine 1996, 335:1950-1955.
91. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine 2006, 354:34-43.
92. Markman M., Bundy B.N., Alberts D.S., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2001, 19:1001-1007.
93. McCarry M.F., Somcio R.J., Stoeltzing O., et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. Journal of Clinical Investigation 2007, 117:2114-2122.